Anti-il2 auto-antibodies as biomarker for diagnosis of an autoimmune disease

The present invention relates to methods for the diagnostic of an autoimmune disease, to peptides and to treatment of autoimmune diseases. Type 1 diabetes (T1D) physiopathology is related to multiple defects in the interleukin-2 (IL-2) pathway that compromise regulatory T cell (Treg cell) homeostasis and therefore immune tolerance. Anti-IL-2 autoantibodies (IL-2A) with neutralizing capacity are associated to T1D, further reinforcing the link between impaired IL-2 bioavailability and T1D. NOD (nonobese diabetic) but not B6 mice present IL-2As with neutralizing activity and IL-2-autoreactive T and B cells. There was also a genetic correlation of low IL-2 levels with high IL-2A titers, pointing to reduced IL-2 levels at the origin of the loss of tolerance to IL-2. Notably, IL-2As accumulate with time and titers at 6 weeks of age correlate with disease incidence, highlighting their disease predictive value. Finally, IL-2As are present at high frequencies in T1D, systemic lupus and rheumatoid arthritis patients, suggesting a potential role of IL-2As in human autoimmunity. Scientific Publication(s): Nat Commun., 2016 Oct 6, Pérol L. et al., Loss of immune tolerance to IL-2 in type 1 diabetes, doi: 10.1038/ncomms13027

Keywords: Autoimmunity, IL-2, Diabetes, Rheumatoid Arthritis, Systemic Lupus, Anti-IL2 related autoimmune disease, ELISA, ELISPOT, Flow Cytometry, Immunoassay, Immunology
Patent Application number: EP14 305 595.2
Nat Commun. 2016 Oct 6;7:13027. doi: 10.1038/ncomms13027.



Business Developper
Sylvestre CHEA
Sylvestre CHEA
Business Development Manager
Patent filling date: 2014-04-22

You might also be interested in